Brief: Galera Announces Topline Results From Phase 2A Aesop Trial Of Avasopasem For Chemoradiotherapy-Induced Esophagitis

Obsidian Therapeutics

02/05/2022 12:14

May 2 (Reuters) - Galera Therapeutics Inc  GRTX.O :
    * GALERA ANNOUNCES TOPLINE RESULTS FROM PHASE 2A AESOP TRIAL
OF
AVASOPASEM FOR CHEMORADIOTHERAPY-INDUCED ESOPHAGITIS
    * GALERA THERAPEUTICS INC - INCIDENCE OF GRADE 3 ESOPHAGITIS
SUBSTANTIALLY REDUCED IN PATIENTS TREATED WITH AVASOPASEM
COMPARED TO LITERATURE
    * GALERA THERAPEUTICS INC - NO GRADE 4 OR 5 ESOPHAGITIS IN
PATIENTS TREATED WITH AVASOPASEM
    * GALERA THERAPEUTICS INC - AVASOPASEM WAS GENERALLY WELL
TOLERATED

Source text for Eikon:  ID:nGNX1qQRwh 
Further company coverage:  GRTX.O 

 ((reuters.briefs@thomsonreuters.com;))